Entering text into the input field will update the search result below

Lilly nabs rights to intranasal glucagon from Canadian pharma firm

Oct. 09, 2015 4:42 PM ETEli Lilly and Company (LLY) StockLLYBy: Douglas W. House, SA News Editor
  • Eli Lilly (NYSE:LLY) acquires the global rights to an intranasal glucagon developed by privately-held Montreal-based Locemia Solutions. The product candidate, currently in Phase 3 development, is a potential needle-free rescue treatment for severe hypoglycemia in diabetic patients treated with insulin.
  • It employs a proprietary glucagon nasal powder formulation that is delivered in an emergency situation via a single-use, ready-to-use device. The caregiver presses a small plunger on the bottom of the device to release the glucagon as a puff in the nose where it is absorbed in the nasal passages.
  • Financial terms of the deal are not disclosed.

Recommended For You

More Trending News

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company